OUTCOME OF TOCILIZUMAB THERAPY IN CHILDREN WITH SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS

S. Balameena¹, R. Ravichandran²

¹Senior Assistant Professor, Department of Rheumatology, MMC, Chennai, Tamilnadu, India. ²Director and Professor, Department of Rheumatology, MMC, Chennai, Tamilnadu, India.

ABSTRACT

BACKGROUND

Globally, 3 lakh children suffer with idiopathic arthritis amongst which systemic is about 10% to 25%. The morbidity of arthritis is severe, mortality is about 2% - 4% and hence different treatment protocols are used.

Aims and Objectives- To find out the clinical and laboratory outcome of Tocilizumab in children with SOJIA.

MATERIALS AND METHODS

It is a descriptive study.

Methods- 24 children of above 3 years to sixteen, who satisfied ILAR criteria for systemic onset, who were already on DMARDs and attended the rheumatic care centre at Rajiv Gandhi Govt. General Hospital were included between March 2014 and March 2017. Other types of JIA and very sick children were excluded. Tocilizumab 8 mg/kg was given every month and the clinical and laboratory assessment, ACR disease activity core set index were done at baseline and at 6 months.

RESULTS

Amongst 24 children, there were 3 dropouts. Tocilizumab was given in 12 doses in 6, 6 doses in 7, 7 doses in 4 and 3 doses in 4.

Male: Female seen as 16: 5 or 3.2: 1. Mean age in the cohort was 9.1 ± 0.729. Mean disease duration was 4.09 ± 0.43. Investigation showed Mean ESR 69.05 ± 3.78 and 38.09 ± 2.52; Mean CRP 25.71 ± 4.06 and 5.43 ± 1.30; Mean WBC 18.92 ± 2.66 and 9.54 ± 0.56; Mean platelet 6.27 ± 3.7 and 4.68 ± 0.189 before and after Tocilizumab therapy.

CONCLUSION

Tocilizumab therapy for systemic JIA reduces systemic activity to a large extent along with articular inflammation, seen as drop in CRP and ESR and platelet with improvement in ACR 30% in this study.

KEY WORDS

JIA, SOJIA and Tocilizumab.

BACKGROUND

Globally, 3 lakh children suffer with idiopathic arthritis, amongst systemic is about 10% to 25%. The morbidity of arthritis is severe and mortality is about 2% - 4% and hence different treatment protocols are available.

JIA is seen in 150 - 200 children in 1 lakh population around the world, which is the commonest occurring rheumatological disorder. Amongst JIA, SOJIA forms 10%-25%. It affects age group of 0 - 5 years. It affects male and female children equally.

In 1987, Sir George Alfred still described this condition as it presents with systemic features like fever in 80%, salmon-pink rash affecting the trunk usually evanescent in 60%, lymphadenopathy in 32%, hepatosplenomegaly in 50%, serositis in 10% and arthritis in 60%, rarely seizures, cholecystitis and uveitis.[1]

Goldberg described 2 out of 11 patients in cohort with myocarditis, pericarditis and pleuritis in 4 out of 11 along with raise of acute phase reactants with transaminitis. It carries severe morbidity of the joints and mortality when persistent systemic features leading to macrophage activation syndrome in some cases.

Immunopathogenesis involves interplay of IL1 and IL6 mediated inflammation of macrophages along with reactive thrombocytosis and anaemia. Hepcidin which prevents reflux of iron from monocytes and liver cells into plasma causes low serum iron and leads to anaemia. Other interleukins MRP8 and 14, MMIF, IL-1B play a role during active inflammation. IL-4 1098 T/G Polymorphisms. MEFV gene mutations, pyrin dysfunction are implicated in initiation of this disease.[1]

Complication

Children develop malnutrition due to poor intake leading to short stature, osteoporosis and school absenteeism. Macrophage activation syndrome due to disease activity and is also seen in viral infections. In long-term disease activity, amyloidosis reported by Immonen et al at 5 yrs. was 88% and at 10 yrs. was 75%.

Due to drugs and immunosuppression children develop infections, Cushingoid features, osteoporosis and anaemia.

Differential Diagnosis

Include familial HLH and periodic syndrome. Synthetic conventional DMARDs were useful in JIA, but when resistant to these drugs anti-cytokine therapy is given.[2]

Financial or Other Competing Interest: None.

Submission 02-01-2018, Peer Review 21-05-2018,
Corresponding Author:
Dr. S. Balameena,
18, 1/708, 1st Street,
MCN Nagar, Thoraipakkam,
Chennai-97, Tamilnadu, India.
E-mail: balameenakumar@gmail.com
DOI: 10.14260/jemds/2018/620
Tocilizumab is an IL-6 monoclonal antibody, which is used to reduce the systemic activity in severe cases and also steroid sparing drugs.\(^3\)\(^,\)\(^4\) Tocilizumab was introduced in Japan for Castleman’s disease in 2005 and then approved for SOJIA in 2008. Same drug was approved in Europe in 2009 and by FDA in 2011 for SOJIA in United States.

Minor side effects being mild URTI, nasopharyngitis in 5% and headaches and diarrhoea in 3% which recovers. Serious adverse event seen as bacterial pneumonias, varicella infection, otitis media and septicemia.

In tender study using Tocilizumab 8 mg/kg in 2 phases, preliminary period for 12 weeks and extended period of 104 weeks (2 yrs.) showed the drug was efficacious. Another ongoing study for 5 years in 17 countries included 12 weeks period and primary endpoint at 12 weeks was absence of fever. They found 85% of children had ACR 30 improvement compared to placebo 24%. They found 71% of children had ACR 70 improvement compared to 8% in placebo. Mild side effects of tocilizumab noticed were URTI, headache, diarrhoea and nasopharyngitis in 5%.\(^5\)\(^,\)\(^6\)

Aims and Objectives: To find out the clinical and laboratory outcome of Tocilizumab in children with SOJIA.

MATERIALS AND METHODS
It is a descriptive study.

Methods

Inclusion Criteria
24 children of above 3 years to sixteen, who satisfied ILAR criteria for systemic onset, who were already on DMARDs and attended the rheumatic care centre at Rajiv Gandhi Govt. General Hospital were included between March 2014 and March 2017.

Exclusion Criteria
Other types of JIA and very sick children were excluded.

Tocilizumab 8 mg/kg was given to the children for every month along with methotrexate and prednisolone 5 mg/day. Physician global assessment of disease activity, patient/parent global assessment of well-being, functional disability, no. of active joints, no. of joints with limitation and ESR assessed. For paediatric ACR, 30 disease activity core set index - 30% improvement of 3 out of 6 variables and not 30% worsening in any one is taken into index calculation. Periodical clinical and laboratory assessment was done at baseline and at 6 months and at 1 year.

The different laboratory parameters were analysed along with clinical index before and after tocilizumab therapy. The laboratory outcomes ESR, CRP along with the clinical paediatric ACR 30% before and after tocilizumab therapy were analysed in descriptive manner and depicted as graphical representation.

RESULTS

Amongst 24 children, 3 dropouts were seen. Tocilizumab was given in 12 doses in 6, 6 doses in 7, 7 doses in 4 and 3 doses in 4. Male: Female seen as 16: 5 or 3.2: 1. Mean age in the cohort was 9.1 ± 0.729. Mean disease duration was 4.09 ± 0.43.

Constitutional features include fever in all the patients 100%, rash in 85.7% and weight loss in 52.4% as shown in Figure 1.
In this study, Mean WBC was 18.92 ± 2.66 and 9.54 ± 0.56 and it also shows encouraging results with drug intervention.

Paediatric ACR 30% improvement core set index also shows positive change with Tocilizumab Fig. 7.

DISCUSSION

Two-year results of the TENDER study demonstrated sustained efficacy of TCZ. In terms of SOJIA, improvement with TCZ occurred early and was maintained over time. About 60% of patients treated with TCZ for 104 weeks were able to discontinue oral corticosteroids and 37% of patients achieved inactive disease status by week 104. No new safety signals emerged during longer term treatment.

Common AEs included infections, neutropenia and increases in alanine transaminase level’s response to TCZ was not affected by disease duration, presence/absence of active systemic features at baseline, number of active joints at baseline, baseline oral corticosteroid dose or concomitant use of MTX and prior treatment with biologics.

In George Fredrick study fever was seen in 80%, but in our cohort it was present in all 100%. In Behren et al study rash was seen in 81%, but in our study it was 85.7%. Joints present was 100% in our study, but in Behren et al it was 60% only. In this study, systemic-onset fever pattern in children is one of the characteristic feature which is the cause for leukocytosis and thrombocytosis. This increased cell counts account for the severe inflammation and disease activity. After Tocilizumab treatment systemic features responded well and there is a marked reduction in cell counts, total WBC and platelets.

The acute phase reactants, ESR and CRP showed reduction after tocilizumab treatment. Paediatric ACR of 30% improvement in disease activity was seen in 6 months with Tocilizumab therapy.

There was no association seen with disease duration and Tocilizumab therapy, which was also seen in TENDER study.

CONCLUSION

TCZ was effective across multiple baseline characteristics. TCZ treatment resulted in a rapid and sustained reduction of inflammation associated with SOJIA.

Tocilizumab therapy for systemic JIA reduces systemic activity to large extent and articular inflammation seen by the drop in CRP and ESR and platelet with improvement in ACR 30% in this study.

Limitation

As this is a small cohort, hence larger data will give more valuable information.

REFERENCES